Patents by Inventor Yan Lou

Yan Lou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoproteasome inhibitors
    Patent number: 11827656
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS
    Publication number: 20230373909
    Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: July 12, 2023
    Publication date: November 23, 2023
    Inventors: Jiping FU, Yan Lou, Yigang He
  • SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS
    Publication number: 20230303509
    Abstract: The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: March 24, 2023
    Publication date: September 28, 2023
    Inventor: Yan LOU
  • Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
    Patent number: 11753366
    Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: September 12, 2023
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES
    Publication number: 20230271979
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Application
    Filed: May 3, 2023
    Publication date: August 31, 2023
    Inventors: Yi Chen, Yan Lou
  • PROCESS OF PREPARING 3-FLUORO-5(((1R,2AR)-3,3,4,4-TETRAFLUORO-1,2A-DIHYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)-OXY)BENZONITRILE
    Publication number: 20230202970
    Abstract: Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 2, 2023
    Publication date: June 29, 2023
    Inventors: Jiping FU, Yan LOU, Yigang HE, Yuetao SHI, Peng ZHOU, Xingxing LI
  • Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
    Patent number: 11680072
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: June 20, 2023
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS
    Publication number: 20230167134
    Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 1, 2022
    Publication date: June 1, 2023
    Inventors: Jiping FU, Yan LOU, Yigang HE
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20230133165
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: May 4, 2023
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile
    Patent number: 11634382
    Abstract: Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: April 25, 2023
    Assignee: NiKang Therapeutics, Inc.
    Inventors: Jiping Fu, Yan Lou, Yigang He, Yuetao Shi, Peng Zhou, Xingxing Li
  • PROCESSES OF MAKING 3-FLUORO-5-(((1S,2aR)-1,3,3,4,4-PENTAFLUORO-2a-HYDROXY-2,2a,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE AND POLYMORPHS THEREOF
    Publication number: 20230115881
    Abstract: The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.
    Type: Application
    Filed: October 11, 2022
    Publication date: April 13, 2023
    Inventors: Charles M. COOK, Jiping FU, Yigang HE, Yan LOU, Rongzhen CHEN, Yan DONG
  • BCL-2 INHIBITORS
    Publication number: 20220402941
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 22, 2022
    Inventors: Yi Chen, Yan Lou
  • Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
    Patent number: 11518772
    Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: December 6, 2022
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES
    Publication number: 20220380302
    Abstract: The present disclosure is directed certain Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and their use in the treatment of diseases mediated by HIF-2? such as cancer. Also provided is the use of HIF-2? inhibitors in combination with a poly (ADP-ribose) polymerase (PARP) inhibitor. In particular, the present disclosure is directed to methods for the treatment of cancers using a HIF-2? inhibitor in combination with a PARP inhibitor and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: July 19, 2022
    Publication date: December 1, 2022
    Inventors: Jiping FU, Yan LOU, Yigang HE, Jing LU
  • Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
    Patent number: 11459340
    Abstract: The present disclosure provides certain tri-substituted heteroaryl derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 4, 2022
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • TRICYCLIC DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS
    Publication number: 20220274914
    Abstract: The present disclosure provides certain tricyclic compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: July 21, 2020
    Publication date: September 1, 2022
    Inventors: Jiping FU, Yan LOU, Yigang HE
  • Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
    Patent number: 11420936
    Abstract: The present disclosure is directed certain Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and their use in the treatment of diseases mediated by HIF-2? such as cancer. Also provided is the use of HIF-2? inhibitors in combination with a poly (ADP-ribose) polymerase (PARP) inhibitor. In particular, the present disclosure is directed to methods for the treatment of cancers using a HIF-2? inhibitor in combination with a PARP inhibitor and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: August 23, 2022
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES
    Publication number: 20220220126
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 14, 2022
    Inventors: Yi Chen, Yan Lou
  • BCL-2 inhibitors
    Patent number: 11365206
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: June 21, 2022
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES
    Publication number: 20220185771
    Abstract: The present disclosure is directed certain Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and their use in the treatment of diseases mediated by HIF-2? such as cancer. Also provided is the use of HIF-2? inhibitors in combination with a poly (ADP-ribose) polymerase (PARP) inhibitor. In particular, the present disclosure is directed to methods for the treatment of cancers using a HIF-2? inhibitor in combination with a PARP inhibitor and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Jiping FU, Yan LOU, Yigang HE